Q-omics provides the consensus-scored RDM1 profile across patient tissues and cancer cell-line models. RDM1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RDM1 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, RDM1 RNA expression shows 18,461 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, BLCA, and LSCC as cancer lineages where RDM1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RDM1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RDM1 survival associations across molecular data types. RDM1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RDM1 RNA expression–survival associations across cancer types. High RDM1 expression shows unfavorable associations in ACC, MESO, KIRP, KICH, LIHC and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RDM1 RNA expression.
This table summarizes RDM1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RDM1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RDM1 shows higher tumor expression in BLCA, KIRC, KIRP, HNSC, THCA and LUAD. The BLCA box plot shows higher RDM1 RNA expression in tumor versus normal tissue (log2 FC = +2.282, t-test p < 0.001).
This table shows molecular features associated with RDM1 in patient tissues and cancer cell lines. In patient samples, RDM1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RDM1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BONE.
